MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.

Dreno, Brigitte; Thompson, John F; Smithers, Bernard Mark; Santinami, Mario; Jouary, Thomas; Gutzmer, Ralf; Levchenko, Evgeny; Rutkowski, Piotr; Grob, Jean-Jacques; Korovin, Sergii; Drucis, Kamil; Grange, Florent; Machet, Laurent; Hersey, Peter; Krajsova, Ivana; Testori, Alessandro; Conry, Robert; Guillot, Bernard; Kruit, Wim H J; Demidov, Lev; Thompson, John A; Bondarenko, Igor; Jaroszek, Jaroslaw; Puig, Susana; Cinat, Gabriela; Hauschild, Axel; Goeman, Jelle J; van Houwelingen, Hans C; Ulloa-Montoya, Fernando; Callegaro, Andrea; Dizier, Benjamin; Spiessens, Bart; Debois, Muriel; Brichard, Vincent G; Louahed, Jamila; Therasse, Patrick; Debruyne, Channa; Kirkwood, John M.
Lancet Oncol; 19(7): 916-929, 2018 07.
Artigo em Inglês | MEDLINE | ID: mdl-29908991